Omega Funds

Omega Funds global life sciences-based investment firm specialized in direct secondary transactions.

Business Model:

Revenue: $0

Employees: 0-0

Rankings

Detailed Omega Funds Information

Geographic Data

Omega Funds headquarters map

Address:

City:

State:

Zip:

Country:

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

7,420,086Website Global Rank

530Website Monthly Traffic

Twitter Followers

Description

Strategically advanced, they enable you to benefit from the expertise of institutional portfolio managers all for a minimum investment of $500! Omega FundsTM give you the opportunity to diversify your investment portfolio and maximize return potential.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
9/2021 Alpine Immune Sciences Private Placement 91M
5/2013 SpineVision Venture Round 10M
12/2013 Visterra Series A 8.1M
1/2005 DBV Technologies Venture Round -
12/2017 Translate Bio Series C 42M
9/2010 Hydrocision Venture Round -
9/2021 Vanqua Bio Series B 85M
7/2017 Trevi Therapeutics Series C 30M
1/2019 Trevi Therapeutics Series C 10M
9/2021 LEXEO Therapeutics Series B 0
7/2014 Paratek Pharmaceuticals Post-IPO Debt 93M
4/2014 JenaValve Technology Series C 0
2/2018 Senti Biosciences Series A 53M
12/2007 Santaris Pharma Series C 30M
9/2021 Anjarium Biosciences Series A 60.4M
12/2019 Anaconda BioMed Series B 22.2M
7/2013 JenaValve Technology Series C 62.5M
1/2023 SoniVie Series C 0
4/2015 Jounce Therapeutics Series B 0
6/2014 BioSilta Venture Round 3.4M
1/2004 Acrux Venture Round -
1/2021 LEXEO Therapeutics Series A 0
7/2021 Artios Pharma Series C 0
9/2017 Replimune Group Series B 55M
1/2011 Exenta Venture Round -
9/2018 First Wave Bio Venture Round 2.6M
9/2021 Thankful Series A 12M
4/2017 Sienna Biopharmaceuticals Series B 0
9/2017 Immunic Therapeutics Series A 11.9M
8/2022 eTheRNA immunotherapies Series B 0
5/2012 Egalet Series B 14.3M
1/2018 Gossamer Bio Series A 100M
7/2020 Alpine Immune Sciences Post-IPO Equity 60M
11/2022 NRG Therapeutics Series A 18.2M
1/2018 ESSA Pharma Post-IPO Equity 5M
10/2017 Visterra Series C 0
11/2020 Imago BioSciences Series C 80M
3/2019 Imago BioSciences Series B 40M
5/2018 Attenua Series A 35M
1/2021 Ikena Oncology Series B 0
1/2012 Translate Bio Series A 20.7M
12/2020 Syros Pharmaceuticals Post-IPO Equity 90.5M
8/2018 Trevi Therapeutics Series C 10.5M
1/2004 CymaBay Therapeutics Venture Round -
8/2015 Kuros Biosciences Post-IPO Equity 15.3M
1/2010 ImpactRx Series E 0
6/2015 XTuit Pharmaceuticals Series A 22M
8/2015 Telesta Therapeutics Venture Round 0
11/2006 Neurotech Series B 0
6/2018 Andrew Alliance Series C 0
11/2015 ObsEva Series B 60M
6/2018 Kronos Bio Seed Round 0
9/2015 Replimune Group Series A 30M
1/2021 Endeavor BioMedicines Series A 62M
7/2015 Translate Bio Series B 0
12/2019 IFM Therapeutics Venture Round 55.5M
3/2015 GelSight Series A -
11/2021 Chroma Medicine Series A 125M
6/2015 Kezar Life Sciences Series A 23M
7/2019 Kronos Bio Series A 105M
2/2020 Spruce Biosciences Series B 88M
6/2020 Checkmate Pharmaceuticals Series C 85M
5/2020 Atea Series D 215M
10/2019 Arcutis Biotherapeutics Series C 94.5M
3/2019 Prevail Therapeutics Series B 50M
4/2022 CDR-Life AG Series A 0
4/2019 Arrakis Therapeutics Series B 75M
2/2021 Nuvation Bio Post-IPO Equity 502M
7/2015 Median Technologies Post-IPO Equity 22M
7/2013 Dicerna Pharmaceuticals Series C 0
10/2020 Scorpion Therapeutics Series A 108M
10/2019 Nuvation Bio Series A 275M
1/2017 Translate Bio Series C 51M
10/2021 Rectify Pharmaceuticals Series A 0
3/2020 Amunix Series A 0
2/2022 Endeavor BioMedicines Series B 101M
10/2014 Visterra Series B 30M
5/2009 Elixir Pharmaceuticals Series D 12M
3/2016 eTheRNA immunotherapies Series A 26.6M
8/2020 Kronos Bio Private Equity Round 155M
9/2022 Photys Series A 0
11/2012 Visterra Series A 26.1M
9/2018 Morphic Therapeutic Series B 0
4/2020 FoRx Therapeutics Seed Round 10.8M
6/2023 Upstream Bio Series B 0
4/2021 Icosavax Series B 0
2/2014 Egalet Post-IPO Equity -
3/2007 Intarcia Therapeutics Venture Round 50M
10/1999 Eve.com Venture Round -
8/2015 Editas Medicine Series B 0
11/2020 Adagio Therapeutics Series B 0
8/2014 Median Technologies Post-IPO Equity 26.4M
11/2009 Oxagen Series C 0
3/2023 Bicara Therapeutics Series B 0
3/2022 Aerium Therapeutics Series A -
6/2023 ARTBIO Seed Round 0
6/2023 Artbio Seed Round 0
7/2017 Kezar Life Sciences Series B 0
1/2021 Scorpion Therapeutics Series B 162M
4/2021 Theseus Pharmaceuticals Series B 0
3/2023 Chroma Medicine Series B 0
3/2005 Celletra Venture Round 5.7M
4/2021 Adagio Therapeutics Series C 0
6/2020 Sana Biotechnology Series A 700M
10/2021 CinCor Pharma Series B 0
6/2021 Synthekine Series B 0
1/2004 Eurobio-Scientific Venture Round -
3/2007 Orqis Medical Series D 12M
5/2015 Replimune Group Seed Round 2M
8/2014 Andrew Alliance Series B -
1/2011 OnPath Technologies Venture Round -
1/2014 NeuroVision Imaging Venture Round -
1/2004 Develogen AG Venture Round -
1/2001 Enanta Pharmaceuticals Venture Round -
3/2018 Prevail Therapeutics Series A 75M
3/2021 Amunix Series B 117M
6/2022 Upstream Bio Series A 200M
6/2020 eTheRNA immunotherapies Series B 0
10/2020 Chord Therapeutics Series A 16M
1/2004 Evotec Venture Round -
1/2007 Achaogen Venture Round -
6/2016 Morphic Therapeutic Series A 0
3/2019 Beam Therapeutics Series B 135M
5/2017 Anaconda BioMed Series A 16.9M
1/2004 Ardana Bioscience Venture Round -
1/2004 CropDesign Venture Round -
7/2018 Gossamer Bio Series B 0
1/2002 Epigenomics Venture Round -
6/2022 Upstream Bio Series A 0
4/2022 CDR-Life AG Series A 0
3/2022 Aerium Therapeutics Series A -
2/2022 Endeavor BioMedicines Series B 0
11/2021 Chroma Medicine Series A 0
10/2021 Rectify Pharmaceuticals Series A 0
10/2021 CinCor Pharma Series B 0
9/2021 Thankful Series A 0
9/2021 Anjarium Biosciences Series A 0
9/2021 Alpine Immune Sciences Post-IPO Equity 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research